Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis

Li, W; Ghamrawi, R; Haidari, W; Feldman, SR

Li, W (reprint author), Wake Forest Sch Med, Dept Dermatol, Med Ctr Blvd, Winston Salem, NC 27157 USA.

ANNALS OF PHARMACOTHERAPY, 0; ():

Abstract

Objective: Risankizumab (Skyrizi), an interleukin-23 (IL-23) antagonist, was approved by the Food and Drug Administration (FDA) for the treatment of m......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索